ANVS Stock Price, Annovis Bio Inc Quote, Chart

Market Summary

USD8.20+0.17

Market Closed

2.12%

ANVS Stock Price

View Fullscreen

ANVS RSI Chart

ANVS Valuation

Market Cap

91.6M

Price/Earnings (Trailing)

-1.93

Price/Sales (Trailing)

1.8K

EV/EBITDA

-1.86

Price/Free Cashflow

-2.59

ANVS Price/Sales (Trailing)

ANVS Profitability

EBT Margin

-129330.36%

Return on Equity

1.4K%

Return on Assets

-608.37%

Free Cashflow Yield

-38.62%

ANVS Fundamentals

ANVS Revenue

Revenue (TTM)

36.8K

ANVS Earnings

Earnings (TTM)

-47.5M

Earnings Growth (Yr)

89.04%

Earnings Growth (Qtr)

95.2%

Breaking Down ANVS Revenue

Last 7 days

38.3%

Last 30 days

-8.8%

Last 90 days

-21.4%

Trailing 12 Months

-39.4%

How does ANVS drawdown profile look like?

ANVS Financial Health

Current Ratio

1.6

ANVS Investor Care

Shares Dilution (1Y)

24.06%

Diluted EPS (TTM)

-5.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	877.3K	597.1K	316.9K	36.8K
2020	840.7K	946.3K	1.1M	1.2M
2019	0	0	0	735.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Annovis Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 20, 2023	mccarthy reid	acquired	-	-	-	-
Nov 20, 2023	hoffman michael b	acquired	1,000,000	6.07	164,745	-
Nov 20, 2023	maccecchini maria-luisa	acquired	249,999	6.07	41,186	president and ceo
Nov 20, 2023	bruck claudine	acquired	6,070	6.07	1,000	-
Nov 20, 2023	white mark k.	acquired	12,140	6.07	2,000	-
Nov 20, 2023	hagopian henry iii	acquired	5,001	6.07	824	chief financial officer
Nov 20, 2023	mccarthy reid	acquired	5,001	6.07	824	-
Nov 20, 2023	hoffman michael b	acquired	999,668	6.1	163,880	-
Nov 20, 2023	bruck claudine	acquired	-	-	-	-
Nov 20, 2023	maccecchini maria-luisa	acquired	249,917	6.1	40,970	president and ceo

Which funds bought or sold ANVS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-223,821	-	-%
May 15, 2024	MARSHALL WACE, LLP	sold off	-100	-609,284	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	42.37	-41,480	399,840	0.01%
May 15, 2024	Royal Bank of Canada	reduced	-90.00	-1,000	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	12.00	12.00	-%
May 15, 2024	STATE STREET CORP	added	23.79	-93,398	346,707	-%
May 15, 2024	MORGAN STANLEY	added	399	58,341	85,157	-%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	reduced	-12.39	-2,360,990	2,975,000	0.01%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-229,673	-	-%
May 15, 2024	Cetera Advisors LLC	new	-	121,678	121,678	-%

Are Funds Buying or Selling ANVS?

Are funds buying ANVS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANVS

No. of Funds

Unveiling Annovis Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 28, 2023	hirschman orin	4.24%	435,000	SC 13G/A
Nov 08, 2023	hirschman orin	5.4%	548,941	SC 13G
Jan 28, 2021	hirschman orin	4.26%	293,358	SC 13G/A
Jul 21, 2020	hirschman orin	7.27%	463,797	SC 13G
Jul 10, 2020	hirschman orin	4.23%	288,290	SC 13G/A
Apr 20, 2020	maccecchini maria-luisa	19.4%	1,414,489	SC 13D
Jan 30, 2020	hirschman orin	7.36%	480,000	SC 13G

Recent SEC filings of Annovis Bio Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 06, 2024	8-K	Current Report
May 06, 2024	DEFA14A	DEFA14A
May 02, 2024	8-K	Current Report
May 01, 2024	424B5	Prospectus Filed
May 01, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Annovis Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Annovis Bio Inc News

Latest updates

Annovis Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-	-	-	7,414	106,131	204,847	586,903	208,261	157,438	-
Operating Expenses	107.4%	5,920,091	2,853,770	2,534,150	3,229,210	1,909,673	1,603,757	2,543,629	583,162	870,962
S&GA Expenses	106.1%	3,035,946	1,472,969	709,648	839,627	497,470	884,859	1,687,151	516,716	108,780
R&D Expenses	108.9%	2,884,145	1,380,801	1,824,502	2,389,583	1,412,203	718,898	856,478	66,446	762,182
EBITDA Margin	-1115.5%	-394	-32.43	-14.13	-9.37	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-107.7%	-5,914,641	-2,848,216	-2,524,602	-3,199,673	-1,704,613	-1,006,354	-2,309,490	-441,590	-201,256
EBT Margin	-1115.5%	-394	-32.43	-14.13	-9.37	-	-	-	-	-
Net Income	-107.7%	-5,914,641	-2,848,216	-2,524,602	-3,199,673	-1,704,613	-1,006,354	-2,309,490	-441,590	-201,256
Net Income Margin	-1115.5%	-394	-32.43	-14.13	-9.37	-	-	-	-	-
Free Cashflow	-1.5%	-1,769,320	-1,743,408	-3,144,563	-2,474,868	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	-23.5%	8.00	10.00	10.00	23.00	26.00	36.00	37.00	40.00	44.00	46.00	48.00	49.00	6.00	8.00	9.00	10.00	11.00	1.00
Current Assets	-23.5%	8.00	10.00	10.00	23.00	26.00	36.00	37.00	40.00	44.00	46.00	48.00	49.00	6.00	8.00	9.00	10.00	11.00	1.00
Cash Equivalents	-45.5%	3.00	6.00	6.00	16.00	17.00	28.00	32.00	36.00	43.00	46.00	47.00	49.00	6.00	8.00	9.00	10.00	11.00	0.00
Liabilities	-37.8%	11.00	18.00	4.00	2.00	5.00	8.00	3.00	1.00	1.00	2.00	1.00	1.00	2.00	1.00	0.00	1.00	1.00	3.00
Current Liabilities	13.8%	5.00	4.00	4.00	2.00	5.00	8.00	3.00	1.00	1.00	2.00	1.00	1.00	2.00	1.00	0.00	1.00	1.00	2.00
Shareholder's Equity	56.7%	-3.35	-7.75	7.00	21.00	20.00	28.00	35.00	39.00	43.00	44.00	47.00	49.00	4.00	8.00	9.00	9.00	11.00	-
Retained Earnings	-0.9%	-111	-110	-88.05	-73.33	-63.79	-54.05	-46.33	-39.90	-33.96	-28.73	-22.81	-19.96	-17.44	-14.24	-12.53	-11.53	-9.22	-8.78
Additional Paid-In Capital	5.3%	108	103	95.00	94.00	84.00	82.00	81.00	79.00	77.00	73.00	69.00	69.00	22.00	22.00	22.00	21.00	20.00	0.00
Shares Outstanding	4.7%	11.00	11.00	9.00	9.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	7.00	-	-	-	-	-
Float	-	-	-	-	92.00	-	-	-	63.00	-	-	-	482	-	-	-	19.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	24.9%	-7,032	-9,364	-9,369	-9,606	-11,626	-3,609	-3,987	-6,694	-3,021	-1,769	-1,743	-3,144	-2,474	-765	-922	-1,311	-970	-52.53	-44.68	-150	-228
Share Based Compensation	-58.7%	365	882	632	1,571	1,542	1,458	2,356	1,904	3,435	3,880	786	8.00	24.00	125	629	1,111	-	-376*	-	-	9.00
Cashflow From Financing	-49.6%	4,415	8,765	-	8,572	7.00	-	-	-	5.00	-	-25.46	46,766	3.00	-	-	-45.39	12,089	-1.86	-3.62	-81.43	530

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ANVS Income Statement

2024-03-31

Statements of Operations - USD ($)	3 Months Ended
Statements of Operations - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 6,514,920	$ 7,786,056
General and administrative	1,294,887	2,183,660
Total operating expenses	7,809,807	9,969,716
Operating loss	(7,809,807)	(9,969,716)
Other income:
Interest income	44,168	232,535
Change in fair value of warrants	6,698,692
Total other income	6,742,860	232,535
Net loss before income taxes	(1,066,947)	(9,737,181)
Income tax expense (benefit)	0	0
Net loss	$ (1,066,947)	$ (9,737,181)
Net loss per share (Note 9)
Basic (dollars per share)	$ (0.10)	$ (1.19)
Diluted (dollars per share)	$ (0.72)	$ (1.19)
Weighted-average number of common shares used in computing net loss per share
Basic	10,625,065	8,194,990
Diluted	10,824,771	8,194,990

ANVS Balance Sheet

2024-03-31

Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,136,968	$ 5,754,720
Prepaid expenses and other current assets	4,676,327	4,453,544
Total current assets	7,813,295	10,208,264
Total assets	7,813,295	10,208,264
Current liabilities:
Accounts payable	4,106,832	1,292,837
Accrued expenses	763,183	2,986,273
Total current liabilities	4,870,015	4,279,110
Warrant liability	6,297,308	13,680,000
Total liabilities	11,167,323	17,959,110
Commitments and contingencies (Note 6)
Stockholders' (deficit)
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding
Common stock - $0.0001 par value, 70,000,000 and 70,000,000 shares authorized and 11,011,299 and 10,519,933 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,101	1,052
Additional paid-in capital	107,970,905	102,507,189
Accumulated deficit	(111,326,034)	(110,259,087)
Total stockholders' (deficit)	(3,354,028)	(7,750,846)
Total liabilities and stockholders' deficit	$ 7,813,295	$ 10,208,264

About Annovis Bio Inc

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

CEO	Dr. Maria L. Maccecchini Ph.D.
WEBSITE	annovisbio.com
INDUSTRY	Biotechnology
EMPLOYEES	5

Annovis Bio Inc Frequently Asked Questions

What is the ticker symbol for Annovis Bio Inc? What does ANVS stand for in stocks?

ANVS is the stock ticker symbol of Annovis Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Annovis Bio Inc (ANVS)?

As of Fri May 17 2024, market cap of Annovis Bio Inc is 91.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANVS stock?

You can check ANVS's fair value in chart for subscribers.

What is the fair value of ANVS stock?

You can check ANVS's fair value in chart for subscribers. The fair value of Annovis Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Annovis Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANVS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Annovis Bio Inc a good stock to buy?

The fair value guage provides a quick view whether ANVS is over valued or under valued. Whether Annovis Bio Inc is cheap or expensive depends on the assumptions which impact Annovis Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANVS.

What is Annovis Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ANVS's PE ratio (Price to Earnings) is -1.93 and Price to Sales (PS) ratio is 1.83 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANVS PE ratio will change depending on the future growth rate expectations of investors.